Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brittany Griffith

Nurse Practitioner, Family Madison, WV Nurse Practitioner

NPI 1104464999 CMS profile 11097184

701 Madison Ave, Madison, WV 25130

Open in the dashboard

General payments

$8,241

470 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brittany Griffith of Madison, WV is reported in the CMS Open Payments database as having received $8,241 across 470 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,633 88
2024 General $1,818 101
2023 General $1,924 106
2022 General $1,680 107
2021 General $1,186 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brittany Griffith
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Brittany Griffith were reported at $1,633. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Brittany Griffith Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,186 $124 $35–$379 $132
2022 $1,680 $141 $44–$430 $149
2023 $1,924 $154 $49–$476 $160
2024 $1,818 $165 $51–$504 $164
2025 $1,633 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,501 54 payments
  2. Pfizer Inc. $1,176 83 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $746 35 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $481 35 payments
  5. Janssen Pharmaceuticals, Inc $430 24 payments
  6. Novartis Pharmaceuticals Corporation $382 21 payments
  7. GlaxoSmithKline, LLC. $376 28 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $349 32 payments
  9. Exact Sciences Corporation $316 15 payments
  10. Novo Nordisk Inc $225 13 payments
  11. Other $2,258 130 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,223 469 payments
  2. Education $17 1 payment
Products named General payments · program years 2021–2025
  1. FARXIGA $908 18 payments
  2. FASENRA $815 11 payments
  3. PREVNAR 20 $779 46 payments
  4. COMIRNATY $765 48 payments
  5. BREZTRI $544 11 payments
  6. JARDIANCE $519 22 payments
  7. ABRYSVO $511 31 payments
  8. XIFAXAN $481 35 payments
  9. XARELTO $430 24 payments
  10. AIRSUPRA $365 8 payments
  11. Other $6,719 413 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 158 drugs

Part D claims

11,309

Median for Nurse Practitioner: 389

Drug cost

$870,693

Median for Nurse Practitioner: $21,885

Branded share of claims

24.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 145 $143,046
Farxiga Dapagliflozin Propanediol Brand 147 $88,837
Jardiance Empagliflozin Brand 79 $63,461
Spiriva Handihaler Tiotropium Bromide Brand 64 $41,320
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 45 $38,658
Eliquis Apixaban Brand 60 $36,370
Janumet Xr Sitagliptin Phos/Metformin Hcl Brand 46 $31,569
Xarelto Rivaroxaban Brand 49 $29,750
Entresto Sacubitril/Valsartan Brand 43 $28,952
Linzess Linaclotide Brand 35 $28,376

The 10 drugs with the highest cost, of 158 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $162
$162 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $160
$160 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $115
$115 79 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $74
$74 — —
ABRYSVO
  • PFIZER INC. $70
$70 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

470 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record